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Abstract
Readouts that define the physiological distributions of drugs in tissues are an unmet challenge and at best imprecise, but are
needed in order to understand both the pharmacokinetic and pharmacodynamic properties associated with efficacy. Here we
demonstrate that it is feasible to follow the in vivo transport of unlabeled drugs within specific organ and tissue compartments
ona platform thatappliesMALDI imagingmassspectrometry totissuesectionscharacterizedwithhigh definition histology. We
have tracked and quantified the distribution of an inhaled reference compound, tiotropium, within the lungs of dosed rats,
using systematic point by point MS and MS/MS sampling at 200 mm intervals. By comparing drug ion distribution patterns in
adjacent tissue sections, we observed that within 15 min following exposure, tiotropium parent MS ions (mass-to-charge; m/z
392.1) and fragmented daughter MS/MS ions (m/z 170.1 and 152.1) were dispersed in a concentration gradient (80 fmol-
5 pmol) away from the central airways into the lung parenchyma and pleura. These drug levels agreed well with amounts
detected in lung compartments by chemical extraction. Moreover, the simultaneous global definition of molecular ion
signatures localized within 2-D tissue space provides accurate assignment of ion identities within histological landmarks,
providing context to dynamic biological processes occurring at sites of drug presence. Our results highlight an important
emerging technology allowing specific high resolution identification of unlabeled drugs at sites of in vivo uptake and retention.
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Introduction
During the last decade, significant technological improvements in
mass spectrometry have had a great impact on drug discovery and
development [1,2]. The direct analysis of tissue sections using matrix-
assisted laser desorption ionization (MALDI) imaging mass spectrom-
etry (IMS) is an emerging technology based on a surface sampling
process. The technology allows analysis and visualization of endoge-
nous proteins, peptides and lipids as well as exogenous molecular
species, such as administered compounds, in their native biochemical
states within the same tissue section with high molecular specificity
[3,4,5,6]. Molecular images are created by rasterizing over the sample
w h i l ec o l l e c t i n gM So rt a n d e mM S( M S / M S )s p e c t r af r o me v e r y
position at a chosen resolution. The localization pattern from
individual molecular species present on the tissue surface can then be
extracted and positioned on the original histological image with the
abundances represented by a concentration dependent color scale.
In the process of drug development for therapy purposes, one of
the key objectives is to optimize the retention of a compound.
There is however a limitation in discovery projects today where
tissue retention is measured by analyzing the total concentration of
drug in tissue homogenates extracted at different time points.
These measurements cannot detect the differential distributions or
relative differences in local concentrations of drugs within specific
tissue compartments and may therefore not reveal the correct
information on why a compound with high retention does not
always provide long effect duration.
Several recent studies have reported MALDI IMS techniques to
localize small molecular mass pharmaceutical compounds in tissue
[5,6,7,8,9]. These reports include applying MALDI IMS to whole
body sections of animals dosed with drugs by oral or intravenous
routes and have demonstrated the potential of differentially
measuring drug/metabolite ion signatures in separate organ
compartments [10,11,12].
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11411In this study we provide the first evidence that compounds
administered by inhaled delivery at standard pharmacological
dosage can be quantitatively detected by MALDI IMS with
accuracy and precision. We have used tiotropium, a bronchodi-
lator used in the management of chronic obstructive pulmonary
disease as a model drug. MALDI IMS is a technology application
that requires no labeling of the native compound structure that
could potentially change the properties of the drug. We
demonstrate that using a conventional MALDI IMS platform,
and dedicated MALDI data processing tools, we can congruently
overlay the array of drug distribution with exact histological
context within specific tissue compartments at 200 mm increments.
Our study demonstrates that a combined approach of MALDI
IMS and high resolution histology can be effectively applied to
quantitatively and qualitatively determine in vivo drug uptake into
targeted tissues.
Results
Detection and distribution of tiotropium in tissue
sections by MALDI IMS
We have used a rodent model to study drug distribution in the
lung using a respiratory inhalation model with the reference
compound tiotropium bromide (TTP), a prescription muscarinic
antagonist that affects bronchodilation. TTP (systematic Interna-
tional Union of Pure and Applied Chemistry, IUPAC, name
((1a,2b,4b,7b)-7-[(hydroxidi-2-thienylacetyl) oxy]-9,9-dimethyl-3-
oxa-9-azoniatricyclo[3.3.1.0
2,4]nonane) is administered as an
inhaled bronchodilator for the treatment of asthma and chronic
obstructive pulmonary disease (COPD).
Initially, both MS and MS/MS methods were used to identify
and then validate the detection of a tiotropium chemical standard
both on MALDI target plates and embedded by spotting onto the
tissue matrix. Structural information and mass identity of TTP,
obtained from the drug standard, showed a characteristic MS
signal (m/z=392.1) and MS/MS fragments at m/z 152.1 and
170.1. We administered TTP to rats for fifteen minutes in a two-
stage flow-past inhalation chamber, as an aerosol of a nebulized
solution, at a dose of 1.1 mg/kg (total delivered lung dose of
50 mg). Serially sectioned slices of lung were dried onto conductive
MALDI plates for MS analysis or for histological analysis. Careful
preparation allowed preservation of the histological compartments
of the conducting airway tree absorbing the inhaled TTP in
individual thin sections (Fig. 1 A, D). The TTP distributions in
lung tissues from dosed animals were analyzed by MALDI IMS at
a resolution of 200 mm in both MS and MS/MS mode (Fig. 1).
The MALDI IMS images showed that TTP was rapidly
transported from the central conducting airways to alveolar beds
in the upper and lower parenchyma. Spectra from lung tissue of
dosed animals displayed matching daughter ions (m/z 152.1 and
170.1) confirming that TTP was indeed detected in lungs of dosed
animals. In MS mode, each pixel was normalized against its total
ion current [13,14]. After normalization of data in MS mode, the
distribution of TTP correlated well with the distribution pattern
obtained by MS/MS imaging on a consecutive section.
Tiotropium concentration in lung tissue sections
We quantified the regional levels of TTP in lung tissue by
simultaneous MALDI IMS analysis of lung tissue from dosed
animals and serial dilutions of the drug deposited on control lung
tissue. Two lung tissue sections, one control and one from dosed
rats, were placed on the same MALDI target slide. Different
concentrations (20 fmol-10 pmol) of drug standards were applied
to the control tissue and both sections were coated with matrix at
Figure 1. The distribution of tiotropium on two central lung tissue sections from a rat after inhalation dosing. The arrows indicate the
route of drug delivery. (A) Photographic image of a rat lung tissue section analyzed by MALDI IMS with (B) the obtained distribution of tiotropium
represented by the parent ion m/z 392.1. (C) A typical MS spectra obtained by MALDI MS analysis on rat lung tissue. (D) Photographic image of a rat
lung tissue section analyzed by MALDI IMS/MS with (E) the obtained distribution of tiotropium represented by the daughter ion m/z 152.1. (F) MS/MS
spectra of tiotropium. The distribution of tiotropium obtained in MS mode (B) correlate very well with the distribution pattern obtained by rastering
over the tissue in MS/MS mode (E). The MALDI matrix CHCA was applied by an automatic sprayer device.
doi:10.1371/journal.pone.0011411.g001
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were analyzed by imaging MALDI MS and MS/MS mode,
respectively, at a spatial resolution of 200 mm. After analysis, the
average intensity values from each TTP deposit were calculated
and a linear regression concentration curve was constructed for
the MS and MS/MS experiment, respectively (Fig. 2). There was a
slight delocalization of TTP ion outside the spotted area for the
highest concentration of drug (Fig. 2). Apart from this, there was
no TTP signal on the non-spotted area of the scanned control
tissue. In MS mode there was linearity between 80 fmol to
2.6 pmol (r=0.983) and in MS/MS mode linearity was obtained
in the range from 80 fmol to 5 pmol (r=0.995).
Spectra from three regions of interest on the tissues from dosed
animals representing high, medium, or low intensities were
extracted (Fig. 2). The average intensities of the pixels in the
regions were calculated after spectra processing and normalization
(MS mode). The obtained values were recalculated to TTP
amounts using the standard curves (Fig. 2). The drug standard
curve obtained from the pre-spotted tissue proved to be linear in
the range corresponding to levels obtained on the tissue isolated
from rats administered with the drug. The levels of TTP in low,
medium and high intensity regions correlated very well between
the MS and MS/MS experiments (Table 1). There was about a six
times higher concentration of TTP in a high intensity region
(,1.3 pmol) than in a low intensity region (,0.2 pmol).
A conventional quantification technique i.e. homogenization of
tissue, extraction of tiotropium, and analysis of tiotropium in lung
tissue extracts using liquid chromatography (LC)-MS/MS includ-
ing standard curves was applied to analyze the amount of
tiotropium in lung tissue after inhalation dosing. The average
concentration of tiotropium in whole lung tissue 15 minutes after
completed inhalation was 8.963.0 nmol/g (pleural (,7 nmol/g)
and central (,12 nmol/g)) corresponding to approximately 8% of
the lung dose. This finding was consistent with a rapid absorption
of tiotropium into blood after administration to the lungs of rats
[15] and the levels correlated well with the concentrations of
tiotropium obtained by MALDI IMS. For the first time, the
regional ion intensities obtained from inhaled TTP could directly
be translated to the distributed drug levels in the tissue sections.
To further investigate the regional dispersion pattern of the
drug in the lung compartments, we compared sections of lung that
represented serial samplings from the pleural surface to the central
core of the lung volumes. As shown in Fig. 3, TTP was uniformly
transported out of the central conducting airways into the small
bronchioles and alveoli, and out to the pleural boundary. This is
shown in the contiguous distribution and relative signal strength of
TTP ions across the lung volume represented in individual lung
slices.
Using open access software, the raw images of ion identities can
be visualized at pixel coordinates corresponding to the original
Figure 2. Estimation of tiotropium levels in lung tissue from rats dosed with the drug (a, b) by comparison to drug standard
samples spotted on control tissue (c, d). Control lung tissue was spotted with different amounts of tiotropium. In total, 20 fmol*, 40 fmol*,
80 fmol, 160 fmol, 320 fmol, 640 fmol, 1.3 pmol, 2.6 pmol, 5 pmol, or 10 pmol were placed on the control tissue (c, d). The spotted controls were
coated with matrix using an automatic spraying device and analyzed on the same MALDI target as the tissue sections from the animals dosed with
tiotropium. One pair of samples (spotted control and dosed tissue) was analyzed in MS mode (a) and one pair was analyzed in MS/MS mode (b).
Average intensities from the tiotropium spiked regions were calculated and a standard curve was constructed from these values for the MS and MS/
MS experiments, respectively (e, f). Three different regions, representing low, medium and high intensity areas, respectively, were selected on the
dosed tissue sections (a, b) and the average intensities of these were matched to the standard curves. The color intensity scales on the controls (c, d)
were set to reflect 0–100% of the maximal peak intensity of the sections from the dosed animals. Hence, this saturated the pixels on the controls with
a higher intensity than the maxima of the dosed tissues. Calculated tiotropium levels from the high, medium, and low intensity regions on the dosed
lung tissue sections (f). The levels obtained in MS mode correlate very well with the levels measured by MS/MS. (*only in MS/MS mode).
doi:10.1371/journal.pone.0011411.g002
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relative appraisals of concentration gradients for individual ion
species throughout the tissue sample. However, these low
resolution raw images are not adequate to allow detailed
histological examination of the exact areas represented by the
ion maps. In order to create an exact histological reference to these
pixel locations, we re-plotted the raw ion maps by pixel location
with colored contour plots based upon gray scale intensity (Fig. 3).
We believe that the concentration scale revealed in these contour
images provides a valid and unbiased estimation of the diffusion
pattern of the drug in vivo relative to the route of delivery and the
activity of drug transporters. This is new and valuable information
that until now could not be obtained using conventional
methodology such as extraction or autoradiography. In this case,
the TPP distribution pattern is remarkable in the context of the
homogeneous pan-alveolar uptake and the speed in which this
occurred in vivo.
Endogenous tissue ions: distributions related to
histology
Acquiring data directly on the tissue sections in MS mode gives
the advantage of obtaining localization patterns of endogenous
peptides, proteins, and phospholipids at each sampling location.
We observed that ,200 specific mass identities between 400–
2200 m/z units could be localized on a single section using the
given MALDI matrix optimized to detect the drug. Many of these
endogenous molecules displayed a defined localization that
correlated to specific tissue compartments (Fig. 4 C, D) while
other compounds were more ubiquitously expressed throughout
the tissue sample (Fig. 4 B, E).
We submitted a variety of these ions to MS/MS analysis in an
attempt to acquire a specific identification and identified multiple
phosphatidylcholine (PC) molecules, such as PC(12:0/0:0)K
+ m/z
478.2, PC (18:0/0:0) m/z 524.3, PC(16:1/10:0) m/z 648.5, and
PC(32:0) m/z 772.5 (Fig. 4 F–I, respectively). Characteristic
fragments in the MS/MS analysis of PCs are neutral losses of
trimethylamine [N(CH3)3], the cyclophosphane ring C2H5O4P,
and the phosphocholine head group fragments (m/z 184, 125,
104, and 86). Potassiated or sodiated PCs, display characteristic
fragments at m/z 163, and m/z 147, respectively [16,17]. To
further understand the anatomical distribution of these identified
ions, we removed the matrix and histochemically stained the lung
sections using conventional hematoxylin and eosin staining and
scanned the slides using high definition digital scanning. We then
matched and re-plotted the ion maps obtained with the original
images of the tissue obtained on the MS instrument with the high
definition images using software that created contour plots based
upon gray scale intensity. We report here our initial observation
that several of the PC ion species showed selective tissue
compartment localization within the lung. For example, PC ion
m/z 674.6 was tightly localized to areas surrounding small
bronchioles. The intensity map of this ion (Fig. 5A) was
subsequently processed into an intensity contour plot that was
superimposed on the histological stained section (Fig. 5B). PC
674.6 was clearly and remarkably associated with bronchiole tissue
(arrows in Fig. 5C), as seen in processed deconvolution image of
the histology slide. MS/MS analysis of the ion m/z 647.6
confirmed the phosphocholine head group fragment but the exact
tail composition of the ion could not be determined.
Discussion
The present study is focused on the new emerging area of
imaging the distributions of drugs in tissue compartments and
presents new possibilities in an area of science that has remained
dormant for decades. It presents an outline for surmounting a very
difficult problem in modern pharmacological studies, that is, the
direct quantitation of drug distributions within cellular environ-
ments. Using an experimental model that surveys sections of the
whole lung lobe at a spatial resolution of 200 mm, we have applied
MALDI IMS to identify and quantify the distribution patterns of a
reference compound inhaled into the lung. This is the first report
of the absolute quantification of an unlabeled drug within the
individual components of a tissue.
The benefits of using MALDI IMS to detect administered drugs
are several. First, the technique does not require exogenous
labeling in order to trace the deposition of the drug. Any chemical
modification of a small molecular weight compound could change
the chemical and biological properties of the native structure. As
such, the measurements by MALDI IMS differ from traditional
molecular imaging of drugs by PET or autoradiography that
require highly specific activity labels for detection and quantifica-
tion. Second, the MALDI IMS has the advantage of delivering
exact mass identifications with high confidence throughout the
entire sample. One can literally follow the mass identities into any
biological compartment that may or may not be related by
biological function or structure to adjacent compartments. Third,
MALDI IMS enables mapping of metabolic products or
Figure 3. The spatial distribution of inhaled tiotropium in
serially sectioned rat lung tissue. Raw MS images (left column)
showing MS localization of inhaled tiotropium (TTP) ion (m/z 392) by
pixel location in serial sections of whole lung moving anatomically in
lung volume from pleural to central to pleural. The arrow indicates
approximate carinal entry point of the drug into the central conducting
airways. Contour plots (right) of the relative concentration gradients of
TPP found in the various lung segments showed a rapid and
homogeneous transport of the drug from airways into the parenchyma
within 15 minutes after exposure. The MALDI matrix CHCA was applied
by an automatic sprayer device.
doi:10.1371/journal.pone.0011411.g003
Table 1. The amount of tiotropium in rat lung tissue from
animals dosed with the drug analyzed using MS or MS/MS
mode.
High int. area Medium int. area Low int. area
MS 1.25 pmol 0.65 pmol 0.20 pmol
MS/MS 1.30 pmol 0.67 pmol 0.23 pmol
The levels presented as low, medium, and high regions correspond to the
marked circled areas in Fig. 1 A, B (int.; intensity).
doi:10.1371/journal.pone.0011411.t001
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sampling, provided that the metabolites have sufficient ionization
efficiency. Neither PET nor autoradiography can distinguish
between a labeled parent and labeled metabolite of a drug at the
site of measurement because it is the label rather than the drug
which is being recorded. In addition to the drug, other ions
representing proteins, peptides and lipids can be obtained at every
sampling site which allows relative comparisons to important
biological comparators present in each compartment. Last, the
spatial resolution of MALDI IMS reported here (200 mm) is
considerably better than the reported resolution values in whole
tissue/organs by positron emission imaging (,5 mm) [18] and
magnetic resonance imaging (,1 mm) [19]. Although MALDI
IMS instruments currently on the market does not yet resolve at
Figure 4. The distribution of endogenous molecules in lung tissue compartments by MS and identification by MS/MS. Photograph of
rat lung tissue (A). Panel B–E displays the distribution of four different endogenous molecules present in (A). These molecules were identified as
different phosphatidylcholines by MS/MS directly on the tissue section. (F) MS/MS spectrum of PC(12:0/0:0)K
+, (G) MS/MS spectrum of PC(18:0/0:0),
(H) MS/MS spectrum of PC(16:1/10:0), (I) MS/MS spectrum of PC(32:0)K
+. The MALDI matrix CHCA was applied by an automatic sprayer device.
doi:10.1371/journal.pone.0011411.g004
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MALDI IMS technology have been performed. Recent reports
indicate technology advancements capable of irradiating and
imaging areas with a resolution as small as ,1 mm [20]. A
MALDI IMS experiment on tissue sections has been carried out
with a resolution of 7 mm in diameter [21]. These improvements
would be of even more utility in studying drug efficacy.
Methods
Animals
The study was conducted in accordance with the European
Communities Council Directive of 24 November 1986 (86/609/
EEC) and was approved by the Lund/Malmo ¨, Sweden Ethical
Committee on Animal Experiments (no. M84-05). Male rats
(n=5, Wistar, Taconic, Denmark) of approximately 350 g body
weight were used. The animals were allowed a 5 days
acclimatization period prior to experimentation. They were kept
in a climate controlled facility (2263uC, 55610% relative
humidity) with 12 hours light-dark cycle. Food and water were
given ad libitum.
Drug administration and tissue collection
Tiotropium was administered as an aerosol of a nebulized
solution to rats at a total dose of 1.1 mg/kg, resulting in a lung
deposited dose of 50 mg. The rats were exposed to the aerosol in
an in-house built two-stage nose-only flow-past inhalation
chamber (Battelle Design) [22]. The lung dose was estimated
from the aerosol concentration, measured by filter sampling at one
port of the inhalation chamber. The amount of compound on the
filter was analyzed by LC-MS/MS and the dose was calculated as
previously described [22].The animals were anesthetized and
sacrificed fifteen min after administration. The lungs were rapidly
dissected out and immediately placed in a fulminating bath of
isopentane/dry ice on hard plastic dish. The lungs were stored at
280uC until sectioned.
Tissue sectioning
The frozen tissues were cut into 15–20 mm thick sections with a
cryo-microtome (Leica CM3050S, Leica Microsystems, Ger-
many). The lungs were cut along the long flat frontal plane of
the left lobe from side to side to get full sections of the central
airways. The sections were transferred to and thaw mounted on
conductive MALDI glass slide dried and stored at 280uC until
further analysis. Before matrix application, the tissues sections
located on the MALDI glass slides (Bruker Daltonics, Bremen,
Germany) were desiccated for 60 min under low vacuum at room
temperature. In some experiments sections on MALDI slides were
stained using conventional hematoxylin and eosin methodology
after MS or MS/MS analysis.
MALDI IMS matrix conditions
For manual spotting, a-cyano-4-hydroxycinnamic acid (CHCA)
was prepared in 50:50:0.1 acetonitrile (ACN)/H2O/trifluoroacetic
acid (TFA) under saturated conditions. The tiotropium drug
standard (0.9 ng/ml) was mixed (1:3) with matrix solution and
0.5 ml were placed onto a MALDI target (steel plate) or a control
lung tissue for analysis. Matrix solution without tiotropium was
placed on tissue sections as control to check for matrix derived
peaks interfering with the mass of the drug.
For the imaging MALDI MS experiments the lung tissue
sections were coated with CHCA matrix solution (5 mg/ml) in
50:50:0.1 ACN/H2O/TFA using an automatic spraying device
(Image Prep, Bruker Daltonics). The Image Prep instrument
deposits matrix solution onto the tissue in a controlled manner.
Briefly, a matrix aerosol is created by vibrational vaporization
under controlled conditions with all droplet diameters #50 mm
and an average droplet size of ,20 mm. A modified customized
method was used for matrix application using the ImagePrep
instrument. The parameters for incubation time, wetness and
matrix thickness were optimized to get the best spectra possible
without delocalization of drug or endogenous compounds on
the tissue. The thickness of the matrix layer was monitored by
the output from the optical sensor. In short, the method
contained four identical phases in which a matrix layer
corresponding to 0.3 V was added by repeating a spray cycle
of 2.5 s followed by 10 s incubation time and 90 s of drying
time (influx of N2). The glass slide was turned 180u in between
each phase and the total matrix layer thickness added was
1.2 V output from the optical sensor. The coated tissue sections
were dried in the desiccator for about 20 min before MS
analysis.
MALDI IMS detection limits and MS/MS verification
The range of detection was investigated by applying different
concentrations of tiotropium onto a control lung section. The drug
was mixed (1:3) with matrix solution and the different amounts of
tiotropium applied to the tissue were 10 pmol, 2.6 pmol,
Figure 5. Localization of endogenous phosphatidylcholines (PC) ions in specific histological compartments. We detected a variety of
PC ion species in the global MALDI IMS scans of lung tissue. Shown here is the distribution profile of PC m/z 674.6 detected as a raw image by pixel
location (A) and as contours of the ion intensity (color code: aqua/high intensity, blue/medium intensity) that have been re-plotted onto scanned
images of the original sample after histological processing and staining (B). PC m/z 674.6 was closely associated with the location of small bronchioles
throughout the lung section. Deconvolution of the H&E stained image (C) allowed clearer visualization of these bronchioles (indicated by arrows)
supporting this observation. The MALDI matrix CHCA was applied by an automatic sprayer device.
doi:10.1371/journal.pone.0011411.g005
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total volume of 0.5 ml. The matrix spots were analyzed in
reflectron mode collecting 300 shots per spot. Using MS mode,
tiotropium was detectable down to 80 fmol and the signal response
was linear up to 2.6 pmol (R
2=0.998).
The drug standard was analyzed in MS/MS mode using a
LIFT method [23]. The LIFT method was calibrated on the
CHCA matrix peak of 379.1 Da and its fragments. The same
method was used to perform MS/MS directly on dosed lung tissue
and spectra were compared to the MS/MS spectra generated
from of the drug standard. Using MS/MS mode, tiotropium was
detectable down to 40 fmol and the signal response was linear up
to 10 pmol (R
2=0.999).
Direct analysis of tiotropium on tissue sections by MALDI
MS and MS/MS
MS experiments were carried out using the UltraFlexII
MALDI-TOF/TOF MS (Bruker Daltonics) equipped with a
solid-state Smartbeam laser operating at 200 Hz. The MS spectra
were acquired in positive reflectron mode. For the initial analyzes
of the manually deposited spots, spectra consisting of 1000 laser
shots were acquired in bundles of 56200 shots and data was
collected between m/z 300–2500 Da, unless stated differently.
Prior to analysis the MS method was calibrated using a standard
peptide mix (Bruker Daltonics) and the matrix cluster peak from
CHCA at m/z 379.1 Da. The MS/MS experiments were
performed using a LIFT method optimized for the drug by
specific tuning of the timing of the LIFT cell and of the precursor
ion selector.
The software Flex Imaging 2.0 (Bruker Daltonics) was used to
set up the acquisition of the imaging experiments. The imaging
MS experiments were performed by collecting spectra (200 or 300
shots) at a resolution of 175–200 mm in the same m/z range as
above.
The spectra were baseline subtracted (Convex hull) and
smoothed (Savitzski golay) in the processing software during
acquisition. In MS mode, all spectra were normalized against total
ion current to reduce influences by i.e. matrix hot spots [14,24].
Here, we define the total ion current as the sum of all intensities in
the mass range analyzed (300–2500 Da). For the sections analyzed
in MS/MS mode, only fragment spectra were acquired from each
spot and 400 laser shots were summed up in a random walk
pattern from each position. The tiotropium fragments with m/z
152 Da and m/z 170 Da were used to visualize the distribution of
tiotropium. The raw data from the imaging experiments were
converted into BioMap format (Novartis, Basel, Switzerland),
using an in-house written script and two dimensional ion density
maps were created using FlexImaging (Bruker Daltonics) or
BioMap.
Estimation of tiotropium levels in tissue sections by
imaging MALDI MS and MS/MS
One section of control lung tissue was placed on the same
MALDI target as a central lung section from a dosed animal.
Different amounts of tiotropium, 20 fmol-10 pmol (in 50:50:0.1
ACN:H2O:TFA) were spotted onto the control tissue in a total
volume of 0.5 ml. The two sets of tissue sections (dosed animal and
spotted control) were then coated with matrix as described above
using the Image Prep and subsequently analyzed by imaging mass
spectrometry in MS and MS/MS mode, respectively.
Average spectra were calculated from each of the tiotropium
spotted regions on the control tissue and the linearity of the
peak intensity (and peak area) of either the precursor ion or the
fragment m/z 152 were calculated. Images were produced and
the color intensity was adjusted so that the intensities on the
spotted control matched the intensities on the dosed tissue.
Average spectra were also calculated for three different areas
on the dosed tissue sections. The areas were chosen as regions
containing low, medium, or high intensity pixels and each area
contained about 20–25 pixels. A linear regression curve was
calculated from the spotted control and the levels of tiotropium
on the dosed tissue were match against the standard curve.
The absolute concentration of TTP on the dosed tissue
sections was estimated by calculating the weight of the tissue
of the selected tissue areas based on the volume of the tissue
(mol/g).
Quantification of tiotropium in lung tissue using LC-MS
analysis
The concentration of tiotropium in lung tissue after
inhalation dosing to rats was quantified after homogenization
of a whole rat lung or lung tissue slices. The lung tissue was
pulverized using a Covaris CryoPrep (Covaris Inc., Woburn,
MA). Ringer buffer solution was added (3 mL buffer per g
tissue) and the compound was extracted using adaptive focused
acoustic ultrasound equipment (Covaris E210, Covaris Inc.).
The samples were precipitated by addition of acetonitrile
containing 1% acetic acid (1:3 v:v), centrifuged and the
supernatant diluted with water (1:4 v:v). Samples were injected
onto a LC system (Shimadzu LC-10ADvp pump and controller
SCL-10Avp, Tokyo, Japan) equipped with a precolumn (Aquasil
5 mM1 0 61 mm; Thermo Scientific, Stockholm, Sweden) and
separation was performed on an analytical column (Aquasil
5 mm, 3061 mm; Thermo Scientific) using a gradient of
acetonitrile/water 99.5/0.5 (v/v) to acetonitrile acetonitrile/
water/acetic acid 95/4.5/0.5 (v/v/v) as mobile phase at a flow
rate of 0.25 mL/min (run time 4 min). Mass spectrometry was
performed on a triple quadrupole mass spectrometer (Sciex API
3000, Concord, Ontario, Canada) with an electrospray
ionization (ESI) source. ESI was performed in the positive ion
mode with nitrogen as the nebulizer, heater and curtain gas.
The detector was operated in the multiple-reaction monitoring
mode using the transitions from the protonated molecules at m/
z 392.1 to 152.1 for tiotropium. Budesonide was used as internal
standard. Tiotropium standard solutions and the internal
standard solution were prepared in acetonitrile.
Identification of endogenous compounds by MS/MS
directly on tissue sections
For the MALDI MS/MS experiments the lung tissue sections
were coated with CHCA matrix solution (5 mg/ml) in 50:50:0.1
ACN/H2O/TFA using a glass spray nebulizer (TLC sprayer,
Sigma Aldrich). At least 20 spray cycles were repeated manually at
a 45 s interval to get a uniform coating. MS/MS analysis directly
on tissue sections were performed using either a MALDI SYNAPT
HDMS system (Waters, Manchester, UK) or a MALDI hybrid
LTQ Orbitrap (Thermo Scientific, San Jose, CA). MS/MS
spectra were collected from all over the tissue sample. The
MALDI SYNAPT was operated in V-mode, m/z range of 50–
1000 and the quadrupole transmission window was set to 1 Da for
precursor ion selection. Using the MALDI Orbitrap ion isolation
and collisional dissociation were achieved in the linear ion trap,
and both precursor and product ions were detected in the
Orbitrap. Full MS data were acquired at the 60,000 resolving
power setting. Tandem MS data were acquired at the 7500
resolving power setting.
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